Skip to content

The Effect of Virtual Reality on Postoperative Pain and Anxiety in Cardiac Surgery.

The Effect of Virtual Reality on Postoperative Pain and Anxiety in Cardiac Surgery.

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06001502
Acronym
VRECOVERY
Enrollment
100
Registered
2023-08-21
Start date
2023-01-01
Completion date
2024-09-01
Last updated
2024-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Bypass Grafting, Heart Surgery, Post Operative Anxiety, Post Operative Pain, Virtual Reality

Brief summary

The objective of this study is to investigate the effect of VR on post-operative pain and anxiety management in cardiac surgery patients undergoing a coronary artery bypass grafting (CABG) procedure. Participants in the intervention group will receive a 20 minute session with the head mounted VR device on post-operative days 1,2 and 3. Participants in the control group will be treated with conventional post-operative care.

Detailed description

Objective: The objective of this study is to investigate the effect of VR on post-operative pain and anxiety management in cardiac surgery patients undergoing a coronary artery bypass grafting (CABG) procedure. Study design: This study is a single-center randomized control trial. Study population: Patients who have undergone a CABG procedure (n=100). Intervention: The intervention group (n=50) will use the VR distraction therapy device at day 1, 2 and 3 after surgery on the general ward. The control group (n=50) will be treated with conventional post-operative pain and anxiety management. Main study parameters/endpoints: The main study parameters at day 1, 2 and 3 after surgery. These are the Numeric Rating Scale (NRS) to assess the effect of pain on mobility, the Quality of Recovery-15 questionnaire, the State-Trait Anxiety Inventory-6 questionnaire and assessment of analgesic use. At follow-up, participants will be called to gather one-time QoR-15 and STAI-6 questionnaire data 6 weeks after the surgery.

Interventions

DEVICEVirtual Reality distraction therapy

The VR device simulates a 3-dimensional virtual enviroment, seeking to immerse the user in virtual surroundings

Sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years or older with written informed consent * Patients undergoing surgical CABG

Exclusion criteria

* Major comorbidities besides coronary artery disease * Complicated surgical procedure * Hearing and/or visual impairments * Psychiatric impairments * Complaints of vomiting and nausea * History of epilepsy * Claustrophobia * Facial wounds and skin defects at site of application * Patients placed in clinical isolation * Readmission to the intensive care unit

Design outcomes

Primary

MeasureTime frameDescription
Numeric Rating Scale (NRS)Post-operative days 1,2 and 3 directly after the VR interventionThe NRS score is a numeric scale in which individuals rate pain from 0 (no pain) tot 10 (worst pain). This is a subjective score which is assessed verbally and used frequently in standard clinical care in multiple medical specialties.
State- Trait Anxiety Inventory 6 questionnairePost-operative days 1,2 and 3 directly after the VR interventionThe STAI-6 questionnaire is a validated psychological inventory designed to measure worry, tension and anxiety in an individual. It is a shortend version of the STAI score
Quality of Recovery-15Post-operative days 1,2 and 3 directly after the VR interventionThe QoR-15 questionnaire is a clinical validated instrument to measure post-operative quality of recovery.

Countries

Netherlands

Contacts

Primary ContactSulayman El Mathari, MD
s.elmathari@amsterdamumc.nl+31205668188

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026